Bristol-Myers Squibb Co.'s new Chief Scientific Officer Thomas Lynch championed the company's lung cancer strategy and laid out immuno-oncology R&D priorities going forward, including a heavy emphasis on translational medicine, during Bristol's first quarter earnings call April 27.
The company reported sales of $4.9bn in the first quarter, which was above expectations and driven by better-than-expected performance of...